FINAL YEAR B.PHARM. SEMESTER-VII (CBCS - 2015 Course) :
SUMMER - 2019
SUBJECT : CLINICAL PHARMACY

Day : Thursday
Date : 09/05/2019

S-2019-4411

Time : 02.00 PM TO 05.00 PM
Max. Marks : 60

N.B.

1) Q.1 and Q.5 are **COMPULSORY.** Out of the remaining attempt any **TWO** questions from each Section.
2) Figures to the right indicate **FULL** marks.
3) Answers to both the sections should be written in **SEPARATE** answer book.

SECTION – I

Q.1 Answer any **FIVE** of the following: **(10)**

a) Explain definition, development and scope of clinical pharmacy.
b) Enlist various markers of Ischemic heart injury with their significance.
c) Give the normal values and significance of AST, ALT and ALP.
d) What is the significance of various microbiological culture sensitivity tests?
e) Write a note of thyroid function test
f) Define the following medical terms: (i) Cyanosis (ii) Stroke.

Q.2 Write a note on fluid and electrolyte balance with significance. **(10)**

Q.3 **a)** What are the steps for drug utilization review? **(06)**
b) Explain in brief about activities of clinical pharmacist. **(04)**

Q.4 Write short notes on any **TWO:** **(10)**

a) Kidney function tests
b) Medication errors
c) Significance of medication history interview

SECTION – II

Q.5 Answer any **FIVE** of the following: **(10)**

a) What is the scope of pharmacovigilance?
b) Enlist different documents required in a clinical trial.
c) What are the needs for conducting literature evaluation?
d) What is rational use of drugs? How to improve it?
e) Enlist different issues about which poison information can be asked?
f) How to conduct QA of drug information provided?

Q.6 What are different parts of a research paper? Describe each part with significance and importance. **(10)**

Q.7 **a)** Give advantages and disadvantages of primary, secondary and tertiary DI resources. **(06)**

b) Define and classify ADRs with appropriate examples. **(04)**

Q.8 Write short notes on any **TWO:** **(10)**

a) Different resources for establishment of DIC.
b) Importance of informed consent and information sheet in clinical trials.
c) Modified systematic approach for answering DI queries.

* * *